Business Context and Reporting Period
This Form 8-K was filed by Capricor Therapeutics, Inc. on December 22, 2017, reporting events occurring on December 20, 2017. The filing addresses Item 5.02 regarding the departure of a Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figure disclosed is a separation payment of $62,500 offered to the departing officer.
Material Changes
- Departure: Leland Gershell resigned as Chief Financial Officer, effective January 1, 2018.
- Appointment: Anthony Bergmann was appointed Chief Financial Officer, effective January 1, 2018. Mr. Bergmann previously served as Vice President-Finance and Treasurer since 2013.
- Compensation: A separation payment of $62,500 is contingent upon Mr. Gershell executing a separation agreement and general release.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on business strategy, or discussion of risks and contingencies beyond the standard disclosure of the executive transition.
Investor Verification Checklist
- Confirm the effective date of the CFO transition (January 1, 2018).
- Verify the execution of the separation agreement by Leland Gershell to confirm the $62,500 payment obligation.
- Review Mr. Bergmann's prior tenure and qualifications as VP-Finance and Treasurer.